Premium
Integrated Target‐Based and Phenotypic Screening Approaches for the Identification of Anti‐Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA
Author(s) -
Ferguson Lindsay,
Wells Geoff,
Bhakta Sanjib,
Johnson James,
Guzman Junitta,
Parish Tanya,
Prentice Robin A.,
Brucoli Federico
Publication year - 2019
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201900217
Subject(s) - mycobacterium tuberculosis , chemistry , enzyme , active site , small molecule , stereochemistry , high throughput screening , biochemistry , ic50 , tuberculosis , in vitro , medicine , pathology
Iron is essential for the pathogenicity and virulence of Mycobacterium tuberculosis , which synthesises salicyl‐capped siderophores (mycobactins) to acquire this element from the host. MbtA is the adenylating enzyme that catalyses the initial reaction of mycobactin biosynthesis and is solely expressed by mycobacteria. A 3200‐member library comprised of lead‐like, structurally diverse compounds was screened against M. tuberculosis for whole‐cell inhibitory activity. A set of 846 compounds that inhibited the tubercle bacilli growth were then tested for their ability to bind to MbtA using a fluorescence‐based thermal shift assay and NMR‐based Water‐LOGSY and saturation transfer difference (STD) experiments. We identified an attractive hit molecule, 5‐hydroxyindol‐3‐ethylamino‐(2‐nitro‐4‐trifluoromethyl)benzene ( 5 ), that bound with high affinity to MbtA and produced a MIC 90 value of 13 μ m . The ligand was docked into the MbtA crystal structure and displayed an excellent fit within the MbtA active pocket, adopting a binding mode different from that of the established MbtA inhibitor Sal‐AMS.